Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Asset Writedowns and Impairment (2019 - 2025)

Biodesix (BDSX) has disclosed Asset Writedowns and Impairment for 7 consecutive years, with $86000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment fell 60.55% year-over-year to $86000.0, compared with a TTM value of $107000.0 through Dec 2025, down 70.36%, and an annual FY2025 reading of $107000.0, down 55.04% over the prior year.
  • Asset Writedowns and Impairment was $86000.0 for Q4 2025 at Biodesix, up from -$78000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $574000.0 in Q2 2022 and bottomed at -$744000.0 in Q4 2022.
  • Average Asset Writedowns and Impairment over 5 years is $42277.8, with a median of $67500.0 recorded in 2024.
  • The sharpest move saw Asset Writedowns and Impairment soared 6533.33% in 2021, then tumbled 1075.0% in 2025.
  • Year by year, Asset Writedowns and Impairment stood at -$193000.0 in 2021, then tumbled by 285.49% to -$744000.0 in 2022, then surged by 64.11% to -$267000.0 in 2023, then soared by 181.65% to $218000.0 in 2024, then crashed by 60.55% to $86000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for BDSX at $86000.0 in Q4 2025, -$78000.0 in Q3 2025, and $26000.0 in Q2 2025.